Hypercholesteremia Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)
Verified date | November 2010 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.
Status | Completed |
Enrollment | 840 |
Est. completion date | May 2006 |
Est. primary completion date | May 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 45 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Maximum IMT >1.2 mm and 3.5 mm at any location in the carotid ultrasound studies conducted at both Visit 2 (Week -4) and Visit 3 (Week -2) - Subjects with age and no other risk factor: Fasting LDL-C at Visit 1 (Week -6) is >120 mg/dL (3.1mmol/L) and <190 mg/dL (4.9 mmol/L) - Subjects with 2 or more risk factors and a 10-year coronary heart disease (CHD) risk < 10%: Fasting LDL-C at Visit 1 (Week -6) is >120 mg/dL (3.1 mmol/L) and <160 mg/dL (4.1 mmol/L) Exclusion Criteria: - Use of pharmacologic lipid-lowering medications (eg, HMG-CoA reductase inhibitors, fibrate derivatives, bile acid binding resins, niacin or its analogues at doses >400 mg) within 12 months prior to Visit 1 (Week -6). - Clinical evidence of coronary artery disease or any other atherosclerotic disease such as angina, MI, TIA, symptomatic carotid artery disease, CVA, CABG, PTCA, peripheral arterial disease, AAA. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind
Country | Name | City | State |
---|---|---|---|
Belgium | Research Site | Brussels | |
Belgium | Research Site | Brussels (Anderlecht) | |
Belgium | Research Site | Leuven | |
Czech Republic | Research Site | Praha 2 | |
Czech Republic | Research Site | Slaný | |
Finland | Research Site | Kuopio | |
France | Research Site | Auboue | |
France | Research Site | Bagnolet | |
France | Research Site | Boulogne Billancourt | |
France | Research Site | Briey | |
France | Research Site | Delme | |
France | Research Site | Drancy | |
France | Research Site | Fresnes En Woevre | |
France | Research Site | Ivry Sur Seine | |
France | Research Site | Jarny | |
France | Research Site | Les Lilas | |
France | Research Site | Marange Silvange | |
France | Research Site | Mars La Tour | |
France | Research Site | Metz | |
France | Research Site | Meudon | |
France | Research Site | Montigny Les Metz | |
France | Research Site | Moutiers | |
France | Research Site | Paris | |
France | Research Site | Paris cedex 14 | |
France | Research Site | St Germain En Laye | |
France | Research Site | Thionville | |
France | Research Site | Yerres | |
France | Research Site | Yutz | |
Germany | Research Site | Essen | Nordrhein-Westfalen |
Germany | Research Site | Essen | |
Germany | Research Site | München | |
Germany | Research Site | München | Bayern |
Netherlands | Research Site | Amsterdam | |
Netherlands | Research Site | Rotterdam | |
Netherlands | Research Site | Utrecht | |
Norway | Research Site | Bekkestua | |
Norway | Research Site | Oslo | |
Norway | Research Site | Skedsmokorset | |
United States | Research Site | Alhambra | California |
United States | Research Site | Boston | Massachusetts |
United States | Research Site | Brooklyn Center | Minnesota |
United States | Research Site | Chicago | Illinois |
United States | Research Site | Cincinnati | Ohio |
United States | Research Site | Glen Mills | Pennsylvania |
United States | Research Site | Houston | Texas |
United States | Research Site | Kirkland | Washington |
United States | Research Site | La Jolla | California |
United States | Research Site | Los Angeles | California |
United States | Research Site | Madison | Wisconsin |
United States | Research Site | Minneapolis | Minnesota |
United States | Research Site | Philadelphia | Pennsylvania |
United States | Research Site | Pittsburgh | Pennsylvania |
United States | Research Site | Renton | Washington |
United States | Research Site | Salisbury | North Carolina |
United States | Research Site | San Diego | California |
United States | Research Site | Santa Ana | California |
United States | Research Site | Seattle | Washington |
United States | Research Site | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States, Belgium, Czech Republic, Finland, France, Germany, Netherlands, Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess the effects of rosuvastatin treatment on the change in the mean maximum intima media thickness (IMT) of the 12 vessel segments: the near & far walls of the CCA, the carotid bulb & the ICA | |||
Secondary | Assess the effects of rosuvastatin treatment on the following variables, with the same analyses being applied to the IMT variables: | |||
Secondary | Change in the mean maximum IMT of the near & far walls of the right & left CCA, carotid bulb, ICA | |||
Secondary | Change in the mean IMT of the near & far walls of the right & left CCA | |||
Secondary | Change in LDL-C, TC, HDL-C, TG, nonHDL-C, ApoB, ApoA-I, nonHDL-C/HDL-C, & ApoB/ApoA-I | |||
Secondary | Change in inflammatory marker: C-reactive protein (CRP) | |||
Secondary | Safety & tolerability, by evaluating the incidence & severity of adverse events & abnormal laboratory values |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05164185 -
The Effect of Remote Ischemic Conditioning in Patients With Hypercholesterolemia
|
N/A | |
Completed |
NCT00329160 -
Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease
|
Phase 4 | |
Completed |
NCT02634151 -
A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins
|
Phase 2 | |
Completed |
NCT02587416 -
Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00153738 -
Phytosterol Supplementation and Cardiovascular Risk
|
N/A | |
Completed |
NCT02722408 -
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
|
Phase 2 | |
Completed |
NCT00239330 -
Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy
|
Phase 3 | |
Recruiting |
NCT01890889 -
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health
|
N/A | |
Completed |
NCT00376584 -
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
|
Phase 3 | |
Completed |
NCT01477944 -
Pattern of Statins Use in Catalonia
|
N/A | |
Completed |
NCT00688454 -
C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
|
N/A | |
Completed |
NCT00347217 -
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
|
Phase 4 | |
Completed |
NCT01354327 -
Effects of Limicol on LDL-cholesterol
|
N/A | |
Completed |
NCT03634436 -
The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02850224 -
Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes
|
N/A | |
Completed |
NCT00408382 -
Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque
|
Phase 4 |